Regulatory Action
GSK Pharma Receives NPPA Demand Notice of ₹3.54 Crore, Company to Challenge Order
NSE
GLAXO
BSE
500660
GlaxoSmithKline Pharmaceuticals Limited has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for ₹3.54 crore relating to alleged overcharging of scheduled formulations. The company stated that the notice has no material impact on its financial operations and intends to file an appeal.
PRICE-SENSITIVE TRIGGER
Event: Receipt of Demand Notice from National Pharmaceutical Pricing Authority (NPPA)
Type: Regulatory Action
Impact: Negative
Immediate Effect: The company has received a regulatory demand notice alleging overcharging of scheduled formulations. GSK Pharma has stated that it will challenge the demand through an appeal.
Key Metrics:
- Total Demand Amount: ₹3,54,12,025
- Alleged Overcharging: ₹1,22,91,163
- Interest Component: ₹2,31,20,862
- Date of Demand Notice: 24 June 2026
- Date of Receipt: 24 June 2026
Highlight:
- Total Regulatory Demand: ₹3.54 Crore
What Happened ?
GlaxoSmithKline Pharmaceuticals Limited has informed the stock exchanges that it received a demand notice dated 24 June 2026 from the National Pharmaceutical Pricing Authority (NPPA).
The notice alleges that the company overcharged scheduled formulations by charging prices higher than those fixed or notified by the Government/NPPA during the relevant period. The total demand amounts to ₹3.54 crore, including the principal amount relating to alleged overcharging and applicable interest.
The company clarified that it does not expect any material impact on its financial operations and intends to file an appeal against the demand order.
Key Details
Regulatory Notice Details:
- Demand notice issued by the National Pharmaceutical Pricing Authority (NPPA).
- Notice dated and received on 24 June 2026.
- Total demand raised is ₹3.54 crore.
- Demand comprises alleged overcharging of ₹1.23 crore and interest of ₹2.31 crore.
- Allegation relates to pricing of scheduled formulations above notified ceiling prices during the relevant period.
- GSK Pharma has stated that it will file an appeal against the demand order.
- The company has disclosed that there is no material impact on its financial operations.
Note:
- The disclosure has been made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Risk Analysis
Summary:
- The demand notice introduces a regulatory compliance matter. While the financial amount is relatively limited, the final outcome will depend on the appellate process.
Key Risks:
- Appeal may not fully succeed.
- Potential financial liability if the demand is upheld.
- Additional legal and compliance costs.
- Regulatory scrutiny over pharmaceutical pricing practices.
Worst Case:
- If the appeal is unsuccessful, the company may be required to pay the full demand amount along with any additional statutory obligations arising from the proceedings.
Risk Level: Low
Company Commentary
- The company received the NPPA demand notice on 24 June 2026.
- The notice relates to alleged overcharging of scheduled formulations above notified prices.
- GSK Pharma stated that there is no material impact on its financial operations.
- The company will file an appeal against the demand order.
Official Exchange Filing: GlaxoSmithKline Pharmaceuticals Limited
